Magnetic resonance imaging (MRI)–guided transurethral ultrasound ablation via the transurethral ultrasound ablation (TULSA)-PRO device (Profound Medical, Mississauga, Canada) has emerged as a promising new option for targeted treatment of localized prostate cancer (PCa).